Rituximab in severe, treatment-refractory interstitial lung disease

Area of Science:

• Pulmonology
• Immunology
• Rheumatology

Background:

• Severe interstitial lung disease (ILD) poses a significant challenge, especially when progressing despite conventional immunosuppression.
• Rituximab, a B-lymphocyte depleting monoclonal antibody, is explored as a potential rescue therapy for such refractory cases.
• Idiopathic pulmonary fibrosis (IPF) is excluded, focusing on other ILD etiologies.

Purpose of the Study:

• To assess the efficacy of rituximab as a rescue therapy in patients with severe, progressive ILD.
• To evaluate changes in pulmonary function following rituximab treatment.
• To analyze the safety profile of rituximab in this patient cohort.

Main Methods:

• Retrospective analysis of 50 patients with severe, progressive ILD (excluding IPF) treated with rituximab from 2010-2012.
• Comparison of pulmonary function tests (forced vital capacity and diffusing capacity for carbon monoxide) before and 6-12 months after rituximab treatment.
• Assessment of ILD aetiologies, including connective tissue disease, hypersensitivity pneumonitis, and miscellaneous conditions.

Main Results:

• Patients presented with severe physiological impairment (median FVC 44.0%, DLCO 24.5%).
• Following rituximab, a median improvement in FVC of 6.7% (P < 0.01) and stability in DLCO (0% change, P < 0.01) were observed at 6-12 months, contrasting with prior decline.
• Two patients experienced serious infections; 10 patients died due to ILD progression.

Conclusions:

• Rituximab demonstrates potential as an effective therapeutic intervention for severe, progressive non-IPF ILD unresponsive to conventional immunosuppression.
• Further prospective, controlled trials are necessary to confirm these findings and evaluate safety outcomes.
• Rituximab may represent a valuable option for patients with limited treatment alternatives.